Suchergebnisse - "Multiple Myeloma drug therapy"

NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma

Autoren: Soncini, Debora Becherini, Pamela Ladisa, Francesco et al.

Quelle: Blood Adv
Blood Advances, Vol 9, Iss 5, Pp 1024-1039 (2025)
Blood advances, vol. 9, no. 5, pp. 1024-1039

Schlagwörter: 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, RC581-951, Multiple Myeloma/drug therapy, Multiple Myeloma/metabolism, Multiple Myeloma/pathology, Humans, NAD/metabolism, Nicotinamide Phosphoribosyltransferase/metabolism, Nicotinamide Phosphoribosyltransferase/genetics, Nicotinamide Phosphoribosyltransferase/antagonists & inhibitors, Melphalan/pharmacology, Melphalan/therapeutic use, Melphalan/administration & dosage, Cell Line, Tumor, Pentosyltransferases/metabolism, Pentosyltransferases/genetics, Cytokines/metabolism, Specialties of internal medicine, Plasma Cell Disorders

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39661983
https://doaj.org/article/597a206371e14f2eafa28f986e80aa00
https://serval.unil.ch/notice/serval:BIB_6A1D49B7E1D9
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6A1D49B7E1D95
https://serval.unil.ch/resource/serval:BIB_6A1D49B7E1D9.P001/REF.pdf
https://hdl.handle.net/11567/1226642
https://doi.org/10.1182/bloodadvances.2024013425

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MAIA long-term outcomes

Autoren: Thierry Facon Philippe Moreau Katja Weisel et al.

Quelle: Leukemia
Leukemia, vol 39, iss 4

Schlagwörter: Adult, Dexamethasone/administration & dosage, Male, Multiple Myeloma/drug therapy, Middle Aged, Prognosis, Dexamethasone, Antibodies, Article, Monoclonal/administration & dosage, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, Humans, Lenalidomide/administration & dosage, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Multiple Myeloma, Lenalidomide, Aged, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40016302
https://escholarship.org/content/qt0pb4t5tq/qt0pb4t5tq.pdf
https://escholarship.org/uc/item/0pb4t5tq

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study: analysis of key subgroups of the MAIA study

Autoren: Philippe Moreau Thierry Facon Saad Z. Usmani et al.

Quelle: Leukemia. 39:710-719

Schlagwörter: Dexamethasone/administration & dosage, Male, Aged, 80 and over, Adult, Multiple Myeloma/drug therapy, Antibodies, Monoclonal, Middle Aged, Prognosis, Antibodies, Dexamethasone, Monoclonal/administration & dosage, Survival Rate, Residual, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Lenalidomide/administration & dosage, Neoplasm, Humans, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Multiple Myeloma, Lenalidomide, Aged, Follow-Up Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39815052
https://portal.findresearcher.sdu.dk/da/publications/2dad082a-7526-4ec2-9b4a-19f24fffd7c1
https://doi.org/10.1038/s41375-024-02506-1

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Autoren: Touzeau, Cyrille Krishnan, Amrita Moreau, Philippe et al.

Weitere Verfasser: Touzeau, Cyrille Krishnan, Amrita Moreau, Philippe et al.

Quelle: Blood. 144:2375-2388

Schlagwörter: Male, Adult, 0301 basic medicine, MESH: Immunotherapy, [SDV]Life Sciences [q-bio], MESH: Multiple Myeloma* / therapy, Immunotherapy, Adoptive, Bispecific* / adverse effects, 03 medical and health sciences, Bispecific* / therapeutic use, Antibodies, Bispecific, MESH: Multiple Myeloma* / drug therapy, 80 and over, Humans, B-Cell Maturation Antigen, MESH: Multiple Myeloma* / mortality, MESH: Treatment Outcome, Aged, MESH: Aged, Aged, 80 and over, MESH: B-Cell Maturation Antigen* / antagonists & inhibitors, 0303 health sciences, MESH: Middle Aged, MESH: Humans, MESH: Antibodies, MESH: Adult, Middle Aged, MESH: Male, Bispecific* / administration & dosage, 3. Good health, [SDV] Life Sciences [q-bio], Treatment Outcome, MESH: B-Cell Maturation Antigen* / immunology, Female, Multiple Myeloma, MESH: Female, Adoptive / adverse effects

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39172760
https://hal.science/hal-04922674v1
https://doi.org/10.1182/blood.2023023616

Health‐Related Quality of Life During Carfilzomib–Lenalidomide–Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study: Findings From the Multiple Myeloma CONPET Study

Autoren: Tine Rosenberg Sören Möller Niels Abildgaard et al.

Quelle: Rosenberg, T, Möller, S, Abildgaard, N, Nørgaard, J N, Lysén, A, Tsykonova, G, Joao, C, Vangsted, A, Schjesvold, F & Nielsen, L K 2025, 'Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation : Findings From the Multiple Myeloma CONPET Study', European Journal of Haematology, vol. 114, no. 3, pp. 517-527. https://doi.org/10.1111/ejh.14358

Schlagwörter: Dexamethasone/administration & dosage, Male, carfilzomib, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Multiple Myeloma/drug therapy, clinical trial, Dyspnea/diagnosis, Middle Aged, multiple myeloma, Oligopeptides/administration & dosage, side effects, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, quality of life, patient-reported outcomes, Quality of Life, Humans, Lenalidomide/administration & dosage, Female, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39638553
https://portal.findresearcher.sdu.dk/da/publications/9173256f-6496-479b-b8dd-2857e0c55df7
https://doi.org/10.1111/ejh.14358
http://www.scopus.com/inward/record.url?scp=85210995772&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/063b7cfa-94c8-4baa-9057-800342db8809
https://doi.org/10.1111/ejh.14358

Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients

Autoren: Badawi, Mohamed Ali Engelhardt, Benjamin Dobkowska, Edyta et al.

Quelle: Invest New Drugs

Schlagwörter: Male, Adult, Aged, 80 and over, Chromosomes, Human, Pair 14, Sulfonamides, Research, Chromosomes, Human, Pair 11, Multiple myeloma, Aged, 80 and over [MeSH], Aged [MeSH], Bridged Bicyclo Compounds, Heterocyclic/administration, Carfilzomib, Dexamethasone/adverse effects [MeSH], Multiple Myeloma/genetics [MeSH], Sulfonamides/adverse effects [MeSH], Sulfonamides/therapeutic use [MeSH], Male [MeSH], Bridged Bicyclo Compounds, Heterocyclic/therapeutic use [MeSH], Oligopeptides/adverse effects [MeSH], Dexamethasone/administration, Venetoclax, Oligopeptides/therapeutic use [MeSH], Multiple Myeloma/drug therapy [MeSH], Bridged Bicyclo Compounds, Heterocyclic/adverse effects [MeSH], Dexamethasone/therapeutic use [MeSH], Female [MeSH], Adult [MeSH], Translocation, Genetic [MeSH], Dose selection, Humans [MeSH], Chromosomes, Human, Pair 11 [MeSH], Exposure-response, Middle Aged [MeSH], Chromosomes, Human, Pair 14 [MeSH], Sulfonamides/administration, Antineoplastic Combined Chemotherapy Protocols/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Oligopeptides/administration, Relapsed/refractory, Middle Aged, Bridged Bicyclo Compounds, Heterocyclic, Dexamethasone, Translocation, Genetic, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Multiple Myeloma, Oligopeptides, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39388024
https://repository.publisso.de/resource/frl:6496067

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis): a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Autoren: María-Victoria Mateos Katja Weisel Valerio De Stefano et al.

Weitere Verfasser: María-Victoria Mateos Katja Weisel Valerio De Stefano et al.

Quelle: Leukemia

Schlagwörter: Male, Adult, Immunology, Female [MeSH], 692/308/2779/109, Follow-Up Studies [MeSH], Aged, 80 and over [MeSH], Multiple Myeloma/pathology [MeSH], Aged [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Middle Aged [MeSH], Neoplasm Recurrence, Local/pathology [MeSH], 692/699/67/1059, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Survival Rate [MeSH], Article, Male [MeSH], Standard of Care [MeSH], Prognosis [MeSH], Multiple Myeloma/mortality [MeSH], Multiple Myeloma/therapy [MeSH], Multiple Myeloma/drug therapy [MeSH], Neoplasm Recurrence, Local/drug therapy [MeSH], article, Drug Resistance, Neoplasm [MeSH], 3211 Oncology and carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, Prospective Studies, Aged, Aged, 80 and over, OUTCOMES, Science & Technology, 3202 Clinical sciences, 1103 Clinical Sciences, Standard of Care, Hematology, Middle Aged, Prognosis, [SDV] Life Sciences [q-bio], Survival Rate, Oncology, ANTIBODY, Drug Resistance, Neoplasm, Female, Neoplasm Recurrence, Local, 3201 Cardiovascular medicine and haematology, Multiple Myeloma, Life Sciences & Biomedicine, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39322709
https://pure.amsterdamumc.nl/en/publications/e814ec41-946c-4b67-a7b5-ce520085f64f
https://doi.org/10.1038/s41375-024-02404-6
https://lirias.kuleuven.be/handle/20.500.12942/768901
https://doi.org/10.1038/s41375-024-02404-6
https://repository.publisso.de/resource/frl:6518595
https://nantes-universite.hal.science/hal-05095631v1
https://nantes-universite.hal.science/hal-05095631v1/document
https://doi.org/10.1038/s41375-024-02404-6

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Autoren: Carretero-Iglesia, Laura Hall, Olivia J Berret, Jérémy et al.

Weitere Verfasser: Carretero-Iglesia, Laura Hall, Olivia J Berret, Jérémy et al.

Quelle: Nat Cancer

Schlagwörter: Cytotoxicity, Immunologic, ADP-ribosyl Cyclase 1 / immunology, T-Lymphocytes, Tumor Escape / drug effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, Multiple Myeloma / immunology, Lymphocyte Activation / drug effects, Multiple Myeloma / drug therapy, 616.07, Lymphocyte Activation, Article, Mice, Cytotoxicity, Immunologic / drug effects, Antigens, Neoplasm, Cell Line, Tumor, T-Lymphocytes / drug effects, Animals, Humans, Tumor Escape / immunology, B-Cell Maturation Antigen, Clinical Trials as Topic, Lymphocyte Activation / immunology, T-Lymphocytes / immunology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, ADP-ribosyl Cyclase 1, Xenograft Model Antitumor Assays, Antigens, Neoplasm / immunology, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Immunotherapy / methods, Tumor Escape, Immunotherapy, B-Cell Maturation Antigen / immunology, Multiple Myeloma

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39261676
https://ora.ox.ac.uk/objects/uuid:c3622b6e-528d-4447-a487-c45f54ddb9e6
https://doi.org/10.1038/s43018-024-00821-1

Mechanisms of resistance to daratumumab in patients with multiple myeloma

Autoren: Katrine Fladeland Iversen

Quelle: Basic & Clinical Pharmacology & Toxicology. 135:401-408

Schlagwörter: 0301 basic medicine, Monoclonal/therapeutic use, Extracellular Vesicles/drug effects, Drug Resistance, Multiple Myeloma/drug therapy, Antineoplastic Agents, CD8-Positive T-Lymphocytes, Complement Activation/drug effects, ADP-ribosyl Cyclase 1/metabolism, Antibodies, resistance, Extracellular Vesicles, 03 medical and health sciences, cancer, Humans, Complement Activation, 0303 health sciences, Antineoplastic Agents/therapeutic use, Antibodies, Monoclonal, daratumumab, ADP-ribosyl Cyclase 1, CD8-Positive T-Lymphocytes/drug effects, 3. Good health, multiple myeloma, Drug Resistance, Neoplasm, Neoplasm, immunotherapy, Multiple Myeloma

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39183578
https://portal.findresearcher.sdu.dk/da/publications/8d2392b8-312e-48c9-841e-eab0443eebde
https://doi.org/10.1111/bcpt.14054

Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations

Autoren: Gerd Rippin Héctor Sanz Wilhelmina E. Hoogendoorn et al.

Quelle: Drug Saf

Schlagwörter: Male, Bias, Research Design, Sample Size, Data Interpretation, Statistical, Bias [MeSH], Humans [MeSH], Prostatic Neoplasms/drug therapy [MeSH], Computer Simulation [MeSH], Confounding Factors, Epidemiologic [MeSH], Research Design [MeSH], Sample Size [MeSH], Randomized Controlled Trials as Topic [MeSH], Male [MeSH], Data Interpretation, Statistical [MeSH], Original Research Article, Multiple Myeloma/mortality [MeSH], Multiple Myeloma/drug therapy [MeSH], Humans, Prostatic Neoplasms, Computer Simulation, Confounding Factors, Epidemiologic, Multiple Myeloma, Randomized Controlled Trials as Topic

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39102176
https://repository.publisso.de/resource/frl:6515231

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study: results from the GMMG-HD6 multicenter phase III study

Autoren: Katharina Kriegsmann Gigi Nu Hoang Quy Ton Mohamed H. S. Awwad et al.

Weitere Verfasser: Katharina Kriegsmann Gigi Nu Hoang Quy Ton Mohamed H. S. Awwad et al.

Quelle: Leukemia

Schlagwörter: Male, Letter, T-Lymphocytes, Regulatory/immunology, Induction Chemotherapy, CD8-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes/immunology, Prognosis, T-Lymphocytes, Regulatory, Progression-Free Survival, Survival Rate, CD28 Antigens, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma/mortality, 38/32, Multiple Myeloma/pathology [MeSH], 692/308/2779/109/1942, Humans [MeSH], Progression-Free Survival [MeSH], T-Lymphocytes, Regulatory/immunology [MeSH], 101, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Survival Rate [MeSH], Male [MeSH], Multiple Myeloma/immunology [MeSH], Induction Chemotherapy [MeSH], Prognosis [MeSH], letter, 13/31, Multiple Myeloma/mortality [MeSH], CD8-Positive T-Lymphocytes/immunology [MeSH], CD28 Antigens [MeSH], 631/67/1990/804, Multiple Myeloma/drug therapy [MeSH], 45, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Multiple Myeloma

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38830959
https://repository.publisso.de/resource/frl:6507734
https://biblio.vub.ac.be/vubir/(20e900e9-6f8c-49b9-af53-a622529e4087).html

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Autoren: Leleu, Xavier Hulin, Cyrille Lambert, Jerome et al.

Weitere Verfasser: Leleu, Xavier Hulin, Cyrille Lambert, Jerome et al.

Quelle: Nat Med

Schlagwörter: Male, Neoplasm, Residual, Humanized / adverse effects, MESH: Bortezomib* / therapeutic use, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Lenalidomide* / administration & dosage, Antibodies, Monoclonal, Humanized, Article, Dexamethasone, MESH: Neoplasm, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Humanized / administration & dosage, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Bortezomib* / administration & dosage, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, MESH: Lenalidomide* / therapeutic use, MESH: Multiple Myeloma* / drug therapy, Humans, Lenalidomide, MESH: Treatment Outcome, Aged, MESH: Aged, MESH: Humans, MESH: Antibodies, MESH: Multiple Myeloma* / pathology, MESH: Male, 3. Good health, Treatment Outcome, Residual, MESH: Antineoplastic Combined Chemotherapy Protocols* / therapeutic use, MESH: Dexamethasone* / administration & dosage, Female, Multiple Myeloma, MESH: Female, MESH: Dexamethasone* / therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38830994
https://univ-rennes.hal.science/hal-04614433v1/document
https://univ-rennes.hal.science/hal-04614433v1
https://doi.org/10.1038/s41591-024-03050-2

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

Autoren: Hose, Dirk Ray, Seemun Rößler, Sina et al.

Weitere Verfasser: Hose, Dirk Ray, Seemun Rößler, Sina et al.

Quelle: J Hematol Oncol
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-20 (2024)

Schlagwörter: collagen, Male, 0301 basic medicine, mice, Neoplasm, Residual, Multiple Myeloma/drug therapy, 610 Medizin, Antineoplastic Agents, Osteolysis, RATS, Bone substitute material, Bortezomib, Multiple myeloma, Osteolytic bone lesions, Local treatment, Minimal residual disease, Bortezomib, Mice, 03 medical and health sciences, Bone substitute material, Silicon Dioxide/chemistry, Multiple myeloma, Cell Line, Tumor, Animals, Humans, Diseases of the blood and blood-forming organs, RC254-282, ddc:610, 0303 health sciences, Minimal residual disease, Research, Local treatment, Antineoplastic Agents/therapeutic use, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Silicon Dioxide, Rats, Osteolytic bone lesions, Cell Line, Tumor [MeSH], Bortezomib/pharmacology [MeSH], Collagen [MeSH], Bortezomib/administration, Humans [MeSH], Rats [MeSH], Antineoplastic Agents/pharmacology [MeSH], Bortezomib/therapeutic use [MeSH], Gels [MeSH], Animals [MeSH], Silicon Dioxide/chemistry [MeSH], Osteolysis/drug therapy [MeSH], Mice [MeSH], Male [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Neoplasm, Residual [MeSH], Multiple Myeloma/drug therapy [MeSH], Bortezomib/therapeutic use, Collagen, RC633-647.5, Multiple Myeloma, Osteolysis/drug therapy, Gels

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39695697
https://doaj.org/article/33c78200635b4a1bb72c9c05f70ea87c
https://repository.publisso.de/resource/frl:6490520
https://biblio.vub.ac.be/vubir/bortezomibreleasing-silicacollagen-xerogels-for-local-treatment-of-osteolytic-bone-and-minimal-residual-disease-in-multiple-myeloma(679c9ced-f872-4105-ba54-c18afbb055ff).html
https://hdl.handle.net/20.500.14017/679c9ced-f872-4105-ba54-c18afbb055ff
https://doi.org/10.1186/s13045-024-01636-4
https://epub.uni-regensburg.de/74544/

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Autoren: Einsele, Hermann Moreau, Philippe Bahlis, Nizar et al.

Weitere Verfasser: Einsele, Hermann Moreau, Philippe Bahlis, Nizar et al.

Quelle: Adv Ther
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Universidad de Salamanca (USAL)
Einsele, H, Moreau, P, Bahlis, N, Bhutani, M, Vincent, L, Karlin, L, Perrot, A, Goldschmidt, H, van de Donk, N W C J, Ocio, E M, Martinez-Lopez, J, Rodríguez-Otero, P, Dytfeld, D, Diels, J, Strulev, V, Haddad, I, Renaud, T, Ammann, E, Cabrieto, J, Perualila, N, Gan, R, Zhang, Y, Parekh, T, Albrecht, C, Weisel, K & Mateos, M-V 2024, 'Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma', Advances in therapy, vol. 41, no. 4, pp. 1576-1593. https://doi.org/10.1007/s12325-024-02797-x

Schlagwörter: 0301 basic medicine, ddc:610, Triple-class-exposed relapsed/refractory multiple myeloma, [SDV]Life Sciences [q-bio], mieloma múltiple, Talquetamab, LocoMMotion, 3. Good health, [SDV] Life Sciences [q-bio], 3201.01 Oncología, 03 medical and health sciences, 0302 clinical medicine, Humans [MeSH], MonumenTAL-1, Original Research, Multiple Myeloma/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], MoMMent, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, 3207.13 Oncología

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38402374
http://hdl.handle.net/10366/166687
https://research.vumc.nl/en/publications/db25202f-8ee6-463e-af7d-abb59f49f7a9
https://hdl.handle.net/10366/166687
https://doi.org/10.1007/s12325-024-02797-x
https://hal.science/hal-04915137v1
https://doi.org/10.1007/s12325-024-02797-x
https://repository.publisso.de/resource/frl:6515511
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39809
https://opus.bibliothek.uni-wuerzburg.de/files/39809/12325_2024_Article_2797.pdf
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-398095
https://doi.org/10.1007/s12325-024-02797-x

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial: results from a randomised, phase 3 trial

Autoren: Mai, Elias K Goldschmid, Hartmut Miah, Kaya et al.

Weitere Verfasser: Mai, Elias K Goldschmid, Hartmut Miah, Kaya et al.

Quelle: The Lancet Haematology. 11:e101-e113

Schlagwörter: Adult, Male, Pneumonia/etiology, Dexamethasone/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Medizin, Multiple Myeloma/drug therapy, Hematopoietic Stem Cell Transplantation, Lenalidomide/adverse effects, Pneumonia, Antibodies, Monoclonal, Humanized, Transplantation, Autologous, Dexamethasone, Bortezomib, Sepsis, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Hematopoietic Stem Cell Transplantation/adverse effects, Multiple Myeloma, Sepsis/chemically induced, Lenalidomide, Bortezomib/adverse effects

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38302221
https://biblio.vub.ac.be/vubir/(0e91d77a-1540-4a1b-95fb-33c2a245e6f5).html
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85183509119
https://doi.org/10.1016/S2352-3026(23)00366-6
https://www.ncbi.nlm.nih.gov/pubmed/38302221

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Autoren: C. Riedhammer F. Bassermann B. Besemer et al.

Quelle: Leukemia
Leukemia : normal and malignant hemopoiesis 38(2), 365-371 (2024). doi:10.1038/s41375-024-02154-5

Schlagwörter: 0301 basic medicine, 0303 health sciences, Medizin, Antineoplastic Agents, Immunotherapy, Adoptive, Immunotherapy, Adoptive [MeSH], Humans [MeSH], Antineoplastic Agents [MeSH], B-Cell Maturation Antigen [MeSH], Retrospective Studies [MeSH], Neoplasms, Plasma Cell [MeSH], Article, 692/699/1541/1990/804, Germany [MeSH], 631/250/251, Antibodies, Bispecific [MeSH], Multiple Myeloma/drug therapy [MeSH], article, ddc, 3. Good health, 03 medical and health sciences, Germany, Antibodies, Bispecific, Humans, B-Cell Maturation Antigen, Multiple Myeloma, Neoplasms, Plasma Cell, Retrospective Studies

Dateibeschreibung: application/pdf; pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38245601
https://repository.publisso.de/resource/frl:6522472
https://mediatum.ub.tum.de/doc/1770232/document.pdf
https://publications.rwth-aachen.de/record/1007160
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85182639025
https://www.ncbi.nlm.nih.gov/pubmed/38245601
https://doi.org/10.1038/s41375-024-02154-5

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Autoren: Luise Fischer Nora Grieb Patrick Born et al.

Quelle: Leukemia

Schlagwörter: Immunotherapy, Adoptive/adverse effects [MeSH], Cytokine Release Syndrome [MeSH], Humans [MeSH], B-Cell Maturation Antigen [MeSH], 13/106, Article, 692/699/1541/1990/804, 13/31, Immunotherapy, Adoptive/methods [MeSH], Multiple Myeloma/drug therapy [MeSH], 631/67/1059/2325, article, CD8-Positive T-Lymphocytes [MeSH], 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, Humans, CD8-Positive T-Lymphocytes, B-Cell Maturation Antigen, Multiple Myeloma, Cytokine Release Syndrome, Immunotherapy, Adoptive, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38184754
https://repository.publisso.de/resource/frl:6521269

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Autoren: Moreau, Philippe Mateos, Maria-Victoria Gonzalez Garcia, Maria Esther et al.

Quelle: Adv Ther
Moreau, P, Mateos, M-V, Gonzalez Garcia, M E, Einsele, H, de Stefano, V, Karlin, L, Lindsey-Hill, J, Besemer, B, Vincent, L, Kirkpatrick, S, Delforge, M, Perrot, A, van de Donk, N W C J, Pawlyn, C, Manier, S, Leleu, X, Martinez-Lopez, J, Ghilotti, F, Diels, J, Morano, R, Albrecht, C, Strulev, V, Haddad, I, Pei, L, Kobos, R, Smit, J, Slavcev, M, Marshall, A & Weisel, K 2023, 'Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma', Advances in therapy. https://doi.org/10.1007/s12325-023-02738-0

Schlagwörter: Triple-class exposed, Comparative Effectiveness Research, Relapsed or refractory multiple myeloma, 3214 Pharmacology and pharmaceutical sciences, Antineoplastic Agents, Research & Experimental Medicine, LocoMMotion, 03 medical and health sciences, 0302 clinical medicine, Physicians, Antineoplastic Combined Chemotherapy Protocols, Physicians [MeSH], Humans [MeSH], Prospective Studies [MeSH], MajesTEC-1, Treatment Outcome [MeSH], Comparative Effectiveness Research [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Teclistamab, Antineoplastic Combined Chemotherapy Protocols [MeSH], Original Research, Multiple Myeloma/drug therapy [MeSH], MoMMent, Humans, Pharmacology & Pharmacy, Prospective Studies, General Clinical Medicine, ddc:610, Science & Technology, 3202 Clinical sciences, 3. Good health, Treatment Outcome, Medicine, Research & Experimental, 1115 Pharmacology and Pharmaceutical Sciences, Multiple Myeloma, Life Sciences & Biomedicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38110653
https://research.vumc.nl/en/publications/7497709a-e731-464a-87cb-5f0042266953
https://repository.publisso.de/resource/frl:6486537

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients: data from five randomized, controlled, phase III trials in 3700 patients

Autoren: Elias K. Mai Thomas Hielscher Uta Bertsch et al.

Quelle: Leukemia
Mai, E K, Hielscher, T, Bertsch, U, Salwender, H J, Zweegman, S, Raab, M S, Munder, M, Pantani, L, Mancuso, K, Brossart, P, Beksac, M, Blau, I W, Dürig, J, Besemer, B, Fenk, R, Reimer, P, van der Holt, B, Hänel, M, von Metzler, I, Graeven, U, Müller-Tidow, C, Boccadoro, M, Scheid, C, Dimopoulos, M A, Hillengass, J, Weisel, K C, Cavo, M, Sonneveld, P & Goldschmidt, H 2023, 'Predictors of early morbidity and mortality in newly diagnosed multiple myeloma : data from five randomized, controlled, phase III trials in 3700 patients', Leukemia. https://doi.org/10.1038/s41375-023-02105-6

Schlagwörter: 2. Zero hunger, Predictors, early morbidity, mortality, newly diagnosed multiple myeloma, Medizin, Middle Aged, Article, 3. Good health, SDG 3 - Good Health and Well-being, Risk Factors, Humans, Morbidity, Multiple Myeloma, 10. No inequality, 692/499, 692/699/67/1990/804, Morbidity [MeSH], Humans [MeSH], Middle Aged [MeSH], Multiple Myeloma/diagnosis [MeSH], Risk Factors [MeSH], Multiple Myeloma/drug therapy [MeSH], article

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38062124
https://research.vumc.nl/en/publications/ae4c0945-9c5e-43da-bc66-26806df6542e
https://pure.amsterdamumc.nl/en/publications/d69ef657-aa22-494f-94f5-77ebaea964c3
https://doi.org/10.1038/s41375-023-02105-6
https://pergamos.lib.uoa.gr/uoa/dl/object/3484449
https://repository.publisso.de/resource/frl:6500769
https://hdl.handle.net/11585/959641
https://www.nature.com/articles/s41375-023-02105-6
https://doi.org/10.1038/s41375-023-02105-6

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020

Autoren: Vincent, Laure Decaux, Olivier Perrot, Aurore et al.

Weitere Verfasser: Vincent, Laure Decaux, Olivier Perrot, Aurore et al.

Quelle: ISSN: 2045-7634.

Schlagwörter: real world, NTE patients, multiple myeloma, first-line therapy, ASCT patients, MESH: ADP-ribosyl Cyclase 1* / antagonists & inhibitors, MESH: ADP-ribosyl Cyclase 1* / immunology, MESH: France / epidemiology, MESH: Hematopoietic Stem Cell Transplantation, MESH: Humans, MESH: Lenalidomide / administration & dosage, MESH: Lenalidomide / therapeutic use, MESH: Male, MESH: Middle Aged, MESH: Multiple Myeloma* / diagnosis, MESH: Multiple Myeloma* / drug therapy, MESH: Multiple Myeloma* / mortality, MESH: Aged, MESH: Multiple Myeloma* / therapy, MESH: Progression-Free Survival, MESH: Prospective Studies, MESH: Transplantation, Autologous, MESH: Treatment Outcome, 80 and over, MESH: Antineoplastic Combined Chemotherapy Protocols* / therapeutic use, MESH: Bortezomib / administration & dosage, MESH: Bortezomib / therapeutic use, MESH: Dexamethasone / administration & dosage, MESH: Dexamethasone / therapeutic use

Relation: info:eu-repo/semantics/altIdentifier/pmid/40087879; PUBMED: 40087879; PUBMEDCENTRAL: PMC11909396

Verfügbarkeit: https://hal.science/hal-05093592
https://hal.science/hal-05093592v1/document
https://hal.science/hal-05093592v1/file/CAM4-14-e70619.pdf
https://doi.org/10.1002/cam4.70619